Feb 24, 2026 10:22AM
Feb 24, 2026 07:01AM
Feb 24, 2026 07:00AM
Feb 24, 2026 07:00AM
Feb 17, 2026 08:00AM
Feb 17, 2026 08:00AM
Dec 8, 2025 07:22AM Fulcrum Therapeutics (FULC) PT Raised at Piper Sandler Post Positive 20mg Pociredir Data
Dec 8, 2025 04:02AM
Dec 6, 2025 05:30PM
Dec 6, 2025 05:30PM
Dec 2, 2025 08:30AM
Nov 3, 2025 04:45PM
Oct 29, 2025 07:00AM
Oct 14, 2025 07:00AM Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
Aug 26, 2025 08:00AM
Jul 29, 2025 06:48AM
Jul 29, 2025 06:48AM
Jul 29, 2025 06:45AM
Jul 29, 2025 06:45AM
Jul 28, 2025 04:01PM
Jul 28, 2025 04:01PM Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Jun 20, 2025 06:58AM
May 29, 2025 04:10PM
May 23, 2025 06:21AM
May 1, 2025 07:00AM
Feb 25, 2025 07:00AM
Nov 13, 2024 07:00AM
Sep 12, 2024 06:55AM Fulcrum Therapeutics (FULC) Reports Topline Results from Phase 3 REACH Trial of Losmapimod
Sep 12, 2024 06:55AM
Aug 19, 2024 07:02AM
Aug 19, 2024 07:00AM
Aug 19, 2024 07:00AM
Jul 31, 2024 07:00AM
May 13, 2024 07:00AM
May 13, 2024 06:00AM Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 8, 2024 08:01AM
May 8, 2024 08:00AM
Mar 18, 2024 07:01AM
Mar 18, 2024 07:00AM
Feb 27, 2024 07:00AM
Nov 7, 2023 07:00AM
Sep 25, 2023 05:00AM Goldman Sachs Starts Fulcrum Therapeutics (FULC) at Neutral, 'Value limited to near-term losmapimod sales'
Sep 7, 2023 08:00AM
Aug 23, 2023 06:50AM
Aug 22, 2023 07:00AM
Aug 22, 2023 07:00AM
Aug 11, 2023 04:53PM
Aug 3, 2023 07:01AM
Aug 3, 2023 06:55AM Fulcrum Therapeutics Inc. (FULC) Appoints Alan A. Musso as CFO
Aug 3, 2023 06:55AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All